Notably, RET fusion-positive cancer cells, but not RET fusion-negative cancer cells, had similar exquisite sensitivity to regorafenib, vandetanib and lenvatinib, which share RET and VEGFR kinases as the only common molecular targets. Here, RET is linked to cancer.